Literature DB >> 2776631

Recovery after severe ethambutol intoxication--psychophysical and electrophysiological correlations.

J Nasemann1, E Zrenner, K G Riedel.   

Abstract

Six patients with severe ocular side effects caused by therapeutical doses of the tuberculostatic drug ethambutol were investigated during the course of recovery with psychophysical and electrophysiological methods. Three patients developed an optic atrophy with permanently reduced vision as a likely consequence of additional risk factors such as diabetes, alcohol abuse, and reduced kidney function. The severity of the neuritis of the optic nerve was not related to the total intake of ethambutol. The likelihood of a permanent ocular damage increased sharply if the visual acuity had dropped below a value of 1/10. permanently prolonged latency of the P-100 component was found in visual evoked potentials even in cases with good recovery from ethambutol-induced damage. The recovery of color vision could be monitored very well with the Farnsworth-Munsell 100-Hue Test which revealed a diffuse impairment of color discrimination with a slight prevalence of the red-green axis. In addition to the known disturbances of the red-green antagonistic neurons, it could be demonstrated by measuring transient tritanopia and spectral sensitivity functions that ethambutol also affects the blue-yellow antagonism at the retinal level.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2776631     DOI: 10.1007/BF00170977

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  24 in total

1.  [Analysis of toxicity in intermittent ethambutol-medication (author's transl)].

Authors:  V Grobb; H Eule; G Hager
Journal:  Klin Monbl Augenheilkd       Date:  1973-07       Impact factor: 0.700

2.  [Visually evoked answers in patients with ethambutol damage].

Authors:  E Adachi-Usami; F J Kellermann; R Makabe
Journal:  Ber Zusammenkunft Dtsch Ophthalmol Ges       Date:  1974

3.  [Studies on the occurrence of optic nerve diseases in the course of myambutol therapy].

Authors:  F Orou; G Sideroff; F Schabel
Journal:  Klin Monbl Augenheilkd       Date:  1972-11       Impact factor: 0.700

4.  [Ocular toxicity of ethambutol].

Authors:  A Bouzas; K Kokkinakis; G Papadakis; G Daikos
Journal:  Ophthalmologica       Date:  1970       Impact factor: 3.250

5.  [Color chart test for early detection and quantitative follow-up of the side effects of ethambutol on the optic nerve: the "65 Test"].

Authors:  W Jaeger; H Krastel; V Seiberth; R Koelb
Journal:  Fortschr Ophthalmol       Date:  1985

6.  Ethambutol changes the color coding of carp retinal ganglion cells reversibly.

Authors:  B W van Dijk; H Spekreijse
Journal:  Invest Ophthalmol Vis Sci       Date:  1983-01       Impact factor: 4.799

7.  [Effects of sodium iodate, iodoacetic acid and ethambutol on electroretinogram and visual evoked potential in rats].

Authors:  S Sato; S Sugimoto; S Chiba
Journal:  J Toxicol Sci       Date:  1984-11       Impact factor: 2.196

8.  Use of contrast sensitivity measurement in the detection of subclinical ethambutol toxic optic neuropathy.

Authors:  J F Salmon; T R Carmichael; N H Welsh
Journal:  Br J Ophthalmol       Date:  1987-03       Impact factor: 4.638

9.  Cone function and cone interaction in hereditary degenerations of the central retina.

Authors:  E Zrenner; J Nowicki; R Adamczyk
Journal:  Doc Ophthalmol       Date:  1986-01-31       Impact factor: 2.379

10.  [Eye examinations during treatment with the new tuberculostatic ethambutol-dihydrochloride Lederle (Myambutol)].

Authors:  H Pahlitzsch; H Tiburtius
Journal:  Klin Monbl Augenheilkd       Date:  1969-02       Impact factor: 0.700

View more
  2 in total

1.  Multifocal electroretinogram demonstrated macular toxicity associated with ethambutol related optic neuropathy.

Authors:  T Y Y Lai; W-M Chan; D S C Lam; E Lim
Journal:  Br J Ophthalmol       Date:  2005-06       Impact factor: 4.638

2.  Risk factors for ethambutol optic toxicity.

Authors:  Katherine Anne Talbert Estlin; Alfredo A Sadun
Journal:  Int Ophthalmol       Date:  2009-02-11       Impact factor: 2.031

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.